SALMONELLA

VolverGo back

Resultados 67 results. LastUpdate Updated on 06/12/2021 [05:44:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days



Page1/3 nextPage   results/page


METHOD FOR PREPARING LIVE ATTENUATED VACCINE BY IRRADIATION AND LIVE ATTENUATED VACCINE COMPOSITION PREPARED BY THE SAME

Publication No.: US2021369829A1 02/12/2021

Applicant:

KOREA ATOMIC ENERGY RES [KR]

CN_113395980_A

Absstract of: US2021369829A1

The present invention relates to a method of preparing a live attenuated vaccine by irradiation and a live attenuated vaccine composition prepared by the same, and more particularly, a method of preparing a live attenuated vaccine by irradiation including irradiating a pathogenic microorganism with a dose of 0.5 to 2 kGy of radiation per single radiation six to fifteen times; and a live attenuated vaccine composition including a pathogenic microorganism attenuated to not be revertant to a wild type by generation of at least one mutation of nucleotide insertion and nucleotide deletion by irradiation.

traducir

METHOD FOR DETERMINING ESCHERICHIA COLI

Publication No.: US2021373016A1 02/12/2021

Applicant:

AQSENS HEALTH OY [FI]

WO_2020089512_PA

Absstract of: US2021373016A1

Disclosed is information related to determining Escherichia coli from a sample such as urine. According to the method, part of sample is admixed with a reagent including a lanthanide(III) ion, a transition metal ion, and a transition metal ion/E. coli-specific M13 phage, and another part of the sample is admixed with the reagent including lanthanide(III) ion, the transition metal ion a wild-type M13 phage. The signals derived from the lanthanide(III) ions in the admixtures were detected with time-gated luminescence measurement. The presence of E. coli in the sample was determined by comparing the lanthanide(III) ion signal in the presence transition metal ion/E. coli-specific M13 phage and the wild type M13 phage.

traducir

MULTIPLEX PRIMER FOR DETECTION OF SALMONELLA AND USES THEREOF

Publication No.: KR20210143580A 29/11/2021

Applicant:

경희대학교산학협력단

Absstract of: KR20210143580A

본 발명은 살모넬라 다중 검출용 조성물, 키트, 이를 이용한 검출방법 및 스크리닝 방법에 관한 것이다.

traducir

GENERIC INERT CARRIER SALMONELLA AND POTENTIAL USE THEREOF

Publication No.: WO2021232799A1 25/11/2021

Applicant:

UNIV YANGZHOU [CN]

CN_111500504_A

Absstract of: WO2021232799A1

Provided are a generic inert carrier Salmonella S9H and the use thereof. The generic inert carrier Salmonella S9H is obtained by means of continuously culturing the inert carrier bacterium S9 in vitro with LB solid and liquid culture media for passage to the fortieth generation. The carrier does not undergo a non-specific agglutination reaction with human-derived, mouse-derived, bovine-derived, pig-derived and poultry-derived (including chicken, duck, goose, turkey, pigeon and quail) sera and whole blood under the number of bacteria at the working concentration, and has the properties of carrying and expressing on the surface different human-derived, mouse-derived, bovine-derived, pig-derived and poultry-derived (including chicken, duck, goose, turkey, pigeon and quail) antigen factors. The carrier can be applied to the development of an indirect agglutination test detection method for simply and quickly detecting human and various animal antigens or infection antibodies, and improves and perfects the technical bottleneck of poor specificity and sensitivity of existing agglutination tests for detecting agglutination antigens and antibodies.

traducir

GENERIC INERT CARRIER ESCHERICHIA COLI AND POTENTIAL USE THEREOF

Publication No.: WO2021232800A1 25/11/2021

Applicant:

UNIV YANGZHOU [CN]

CN_111560341_A

Absstract of: WO2021232800A1

Provided are a generic inert carrier Escherichia coli and the use thereof. An inert carrier bacterium SE1 is continuously cultured in vitro with LB solid and liquid culture media for passage to the fortieth generation or above, and a strain obtained from the fortieth generation or above (including the forty-first generation to the sixtieth generation) is named as a generic inert carrier Escherichia coli SE1H. The generic inert carrier is characterized in that the carrier does not undergo a non-specific agglutination reaction with human-derived, mouse-derived, bovine-derived, pig-derived and poultry-derived sera and whole blood under the number of bacteria at the working concentration, and has the properties of carrying and expressing on the surface different human-derived, mouse-derived, bovine-derived, pig-derived and poultry-derived antigen factors. The carrier can be applied to the development of an indirect agglutination test detection method for simply and quickly detecting human and various animal antigens or infection antibodies, and improves and perfects the specificity and sensitivity of existing agglutination tests for detecting agglutination antigens and antibodies.

traducir

CRP CAPTURE/DETECTION OF BACTERIA

Publication No.: EP3912986A2 24/11/2021

Applicant:

HARVARD COLLEGE [US]

US_2021277079_A1

Absstract of: EP3912986A2

Described herein are engineered microbe-targeting molecules, microbe-targeting articles, kits comprising the same, and uses thereof. Such microbe-targeting molecules, microbe-targeting articles, or the kits comprising the same can bind or capture of a microbe or microbial matter thereof, and can thus be used in various applications, such as diagnosis or treatment of an infection caused by microbes in a subject or any environmental surface.

traducir

MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS THEREOF AND APPLICATIONS

Publication No.: EP3912619A1 24/11/2021

Applicant:

CHILDRENS MEDICAL CENTER [US]

US_2021332090_A1

Absstract of: EP3912619A1

The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.

traducir

RECOMBINANT STRAINS AND MEDIUM FORMULATION FOR ENHANCING SECRETION TITER USING A TYPE III SECRETION SYSTEM

Publication No.: EP3911667A1 24/11/2021

Applicant:

UNIV NORTHWESTERN [US]

WO_2020150533_A1

Absstract of: WO2020150533A1

The present disclosure provides a recombinant Salmonella strain having a Type III secretion system (T3SS) comprising mutation which enhance protein expression and production. Additionally, methods and kits for using the recombinant Salmonella strain for producing a protein of interest are provided. Additionally, an optimized medium that increases protein expression in a Salmonella strain having a Type III secretion system (T3SS) is provided.

traducir

一种注射用水包油型乳剂黏膜疫苗及其制备方法和应用

Publication No.: CN113679831A 23/11/2021

Applicant:

四川大学

Absstract of: CN113679831A

本发明公开了一种注射用水包油型乳剂黏膜疫苗及其制备方法和应用,属于生物制药领域。所述注射用水包油型乳剂黏膜疫苗包括:初乳、全反式维甲酸、金属离子化合物、抗原。所述全反式维甲酸可以溶解在制备初乳的油相中,也可以分散在含pH缓冲液的初乳中,金属离子化合物吸附于初乳表面,抗原在制备的过程中加入并通过金属离子化合物吸附于初乳表面,实现抗原和疏水性全反式维甲酸的共同包载。本发明提供的水包油型乳剂黏膜疫苗,通过注射免疫的方式,与已有方法的单一激活相比,能同时实现体液免疫、细胞免疫和黏膜免疫的多重保护,具有广阔的应用前景。

traducir

INERT CARRIER INDIRECT AGGLUTINATION TEST DETECTION SYSTEM AND APPLICATION THEREOF

Publication No.: WO2021227514A1 18/11/2021

Applicant:

UNIV YANGZHOU [CN]

CN_111537712_A

Absstract of: WO2021227514A1

Provided are an inert carrier indirect agglutination test detection system and an application thereof. Specifically, the indirect agglutination test detection system comprises an inert carrier bacteria S9 and a complex S9-P that expresses and carries a P antigen factor on the surface thereof. The inert carrier indirect agglutination test detection system only carries the P antigen factor, and has a positive particle agglutination reaction that is visible to the naked eye with the whole blood or serum of Salmonella pullorum and Salmonella gallinarum-infected chickens at certain concentration conditions, and has no non-specific cross-agglutination reactions with the serum or whole blood of different background chicken sources without Salmonella pullorum and Salmonella gallinarum infections. S9-P is based on a glass plate agglutination reaction operation platform. Agglutination reaction particles are visible to the naked eye, and the result is clear and easy to determine. The test and result determinations are complete within two minutes. S9-P is suitable for the targeted and specific detection of Salmonella pullorum and Salmonella gallinarum in chicken flocks, and has good application prospects in the field monitoring and diagnosis of chicken flocks.

traducir

Klebsiella vaccine and methods of use

Publication No.: AU2020263592A1 18/11/2021

Applicant:

UNIV CORNELL [US]

WO_2020220014_A1

Absstract of: AU2020263592A1

Provided are compositions and methods that include a

traducir

METHOD FOR PREPARING LIVE ATTENUATED VACCINE BY RADIATION AND LIVE ATTENUATED VACCINE COMPOSITION PREPARED THEREBY

Publication No.: EP3909610A1 17/11/2021

Applicant:

KOREA ATOMIC ENERGY RES [KR]

US_2021369829_A1

Absstract of: EP3909610A1

The present invention relates to a method of preparing a live attenuated vaccine by irradiation and a live attenuated vaccine composition prepared by the same, and more particularly, a method of preparing a live attenuated vaccine by irradiation including irradiating a pathogenic microorganism with a dose of 0.5 to 2kGy of radiation per single radiation six to fifteen times; and a live attenuated vaccine composition including a pathogenic microorganism attenuated to not be revertant to a wild type by generation of at least one mutation of nucleotide insertion and nucleotide deletion by irradiation.

traducir

SYNTHETIC BINDING AGENTS FOR LIMITING PERMEATION THROUGH MUCUS

Publication No.: US2021347885A1 11/11/2021

Applicant:

UNIV NORTH CAROLINA CHAPEL HILL [US]
MUCOMMUNE LLC [US]

CN_113166236_A

Absstract of: US2021347885A1

Synthetic binding agents for reducing the fraction of targets that can permeate through mucus and/or freely divide, and methods of reducing mucosal permeation and/or free division of a target using these synthetic binding agents.

traducir

CELLULAR MATERIAL DETECTION PROBES

Publication No.: WO2021224640A1 11/11/2021

Applicant:

FLUORETIQ LTD [GB]

Absstract of: WO2021224640A1

There is provided compositions for the detection of target cellular material, the composition comprising: a chemically modified substrate; at least one binding moiety, wherein the binding moiety comprises a glycan; and at least one linker covalently linked to the substrate and the binding moiety by a first and second bond. There is also provided methods of preparation of such compositions and methods for detection of target cellular material, such as for detection of pathogenic microorganisms.

traducir

Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same

Publication No.: US2021346443A1 11/11/2021

Applicant:

BIOATLANTIS LTD [IE]

Absstract of: US2021346443A1

The present invention relates to a composition and methods comprising an amount of β-glucans and α-fucans, wherein the combination is synergistic to at least one of: increase growth of beneficial microbes and reduced levels of harmful microbes selected from E. coli or Salmonella in animal or human intestines, improve gut structure, reduce gut inflammation, improved nutrient digestibility, improve mineral absorption and growth performance, or reduce gut infection and inflammation.

traducir

ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF

Publication No.: JP2021530220A 11/11/2021

Applicant:

アクティム・セラピューティクス・インコーポレイテッドActymTherapeutics,Inc.

BR_112021000315_A2

Absstract of: WO2020014543A2

Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella or modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin- and/or pagP -. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd -, purI - and msbB -. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment or tumor-resident immune cells and/or induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.

traducir

MODIFIED IMMUNE CELLS EXPRESSING FLAGELLIN POLYPEPTIDE

Publication No.: EP3906047A1 10/11/2021

Applicant:

NANJING LEGEND BIOTECH CO LTD [CN]

CN_113164578_A

Absstract of: WO2020140973A1

Provided are modified immune cells expressing a flagellin polypeptide capable of binding to a toll-like receptor. The modified immune cell further comprises an engineered receptor. Also provided are methods and pharmaceutical compositions for cancer treatment using the modified immune cells.

traducir

IMMUNOGENIC COMPOSITIONS COMPRISING LAWSONIA INTERCELLULARIS

Publication No.: EP3906941A1 10/11/2021

Applicant:

BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC [US]

CN_101175509_A

Absstract of: EP3906941A1

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

traducir

LASER-INDUCED GRAPHENE ELECTROCHEMICAL IMMUNOSENSORS

Publication No.: WO2021222250A1 04/11/2021

Applicant:

UNIV IOWA STATE RES FOUND INC [US]

US_2021332489_A1

Absstract of: WO2021222250A1

Apparatus and methods of fabrication and use of a highly sensitive and label-free laser-induced graphene (LIG) electrode (10) functionalized with biorecognition agents (e.g. antibodies) (18) to electrochemically quantify a target species (e.g. foodborne pathogen Salmonella enterica serovar Typhimurium). In one example, the LIG electrodes are produced by laser induction on polyimide film (12) in ambient conditions, and circumvent need for high-temperature, vacuum environment, and metal seed catalysts commonly associated with graphene-based electrodes fabricated via chemical vapor deposition processes. After functionalization, the LIG biosensors detect a target species across a wide linear range with a low detection limit, and quick response time without need for sample pre-concentration or redox labeling. These LIG immunosensors displayed high selectivity by non-significant response to other bacteria strains, and demonstrate LIG-based electrodes can be used for electrochemical biosensing and immunosensing. One example for rapid, low-cost pathogen detection in food processing facilities before contaminated foods reach the consumer.

traducir

IDENTIFYING AND CLASSIFYING MICROORGANISMS

Publication No.: WO2021222182A1 04/11/2021

Applicant:

UNIV TEXAS [US]

Absstract of: WO2021222182A1

In a general aspect, microorganisms [e.g., bacteria, etc.) are identified and detected. In some examples, a liquid solvent is supplied through a first channel of a sampling probe to an internal reservoir of the sampling probe; a fixed volume of the liquid solvent in the internal reservoir is held in direct contact with a sample surface for a period of time to form a liquid analyte; gas is supplied to the internal reservoir through a second channel of the sampling probe; the liquid analyte is extracted from the internal reservoir through a third channel of the sampling probe; the liquid analyte is transferred to a mass spectrometer; the mass spectrometer processes the liquid analyte to produce mass spectrometry data; and the mass spectrometry data are analyzed to detect and identify a microorganism [e.g., bacteria, fungi, or another type of microorganism) present at the sample surface.

traducir

LIVE SELF-DESTRUCTING BACTERIAL ADJUVANTS TO ENHANCE INDUCTION OF IMMUNITY

Publication No.: WO2021222696A1 04/11/2021

Applicant:

UNIV FLORIDA [US]

Absstract of: WO2021222696A1

Disclosed herein are unique adjuvant compositions comprising an attenuated derivative of a self- destructing bacterial pathogen that undergoes lysis in vivo. In exemplary embodiments, the bacterial pathogen is a Salmonella spp. Also disclosed are methods for enhancing an immune response using the adjuvants disclosed herein.

traducir

FAST AND PORTABLE MICROFLUIDIC DETECTION SYSTEM AS AN ALTERNATIVE TO SALMONELLA'S CLASSICAL CULTURE METHOD

Publication No.: EP3902929A1 03/11/2021

Applicant:

TUEBITAK [TR]

WO_2020136595_PA

Absstract of: WO2020136595A1

Every year, approximately 94 million cases of Salmonella gastroenteritis, with 155000 deaths, are reported each year and 85% of them reported to be food-borne. Investigation of the foods whether they are clean for Salmonella and sensitivity, easy applicability, absence of false positivity and negativity and the speed are the features sought in the analysis method for this investigation. It is not desirable for analysis to detect the presence of dead bacteria in food. Although the final product does not contain microbiologically harmful live bacteria during the food process, the detection of dead bacteria transmitted before the process causes the food product to be unfairly diagnosed as harmful. To prevent this situation, the analysis kits depending on molecular methods, increase their microorganism detection levels up to to 104 while reducing their sensitivity. Since the molecular methods cannot discriminate dead and live organisms, a confirmation test is required to prove that the positive result of the analysis belongs to the live bacteria in the food, which results in additional cost and time loss. In the same way, it is necessary to verify whether the colonies that grow in the gold standard culture method, belong to Salmonella bacteria. In the developed system; 105 dead bacterial DNA is eliminated in the food to prevent false positive results and the minimum detection limit is 10 bacteria. Also, in developed system, 4 primers specific to 6 regions of DNA are used. Therefo

traducir

ANTIBODIES TARGETING A GALACTAN-BASED O-ANTIGEN OF K. PNEUMONIAE

Publication No.: RU2021131224A 03/11/2021

Applicant:

ХФармасьютикалзАвстрияГмбХ

BR_112017017553_A2

Absstract of: WO2016131503A1

The invention provides for an isolated antibody that specifically recognizes a galactan-III epitope of the lipopolysaccharide (LPS) O-antigen structure of Klebsiella pneumoniae, which epitope is incorporated in galactan-III repeating units, wherein the galactan-III repeating unit is a branched galactose homopolymer of Formula (I). The invention further provides for a pharmaceutical or diagnostic preparation comprising said antibody, and a method of producing said antibody.

traducir

VIRULENCE ATTENUATED BACTERIA FOR TREATMENT OF MALIGNANT SOLID TUMORS

Publication No.: EP3903813A1 03/11/2021

Applicant:

UNIV BASEL [CH]

JP_2019500026_A

Absstract of: EP3903813A1

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains for use in a method of treating a malignant solid tumor in a subject.

traducir

BACILLUS SUBTILIS FOR ANIMAL FEED

Nº publicación: US2021329944A1 28/10/2021

Applicant:

CHR HANSEN AS [DK]

WO_2019141815_A1

Absstract of: US2021329944A1

The present invention provides a Bacillus subtilis strain deposited as DSM 32685 and mutant strains thereof which are susceptible to relevant antibiotics, have inhibitory activity against Staphylococcus, Streptococcus, E. coli and Salmonella enterica and have the ability to facilitate degradation of non-starch polysaccharides and thereby increase the amount of available oligosaccharides (sugar) in animal feed.The invention further relates to a composition comprising at least one Bacillus subtilis strain of the invention and optionally further bacteria, and/or one or more types of yeast.The composition may be a probiotic, Direct Fed Microbial (DFM), a premix, an animal feed additive, or an animal feed such as complete feed, e.g. a canine complete feed. The composition can be used in the prevention, reduction or control of a bacterial colonization or infection or for increasing digestibility of an animal feed, in particular a feed for a monogastric animal, such as feed for a companion animal, e.g. a domestic dog or cat.

traducir

Page1/3 nextPage results/page

punteroimgGo back